Biological and genetic factors associated to treatment resistance in aggressive B-cell lymphoma

10^th International Conference on CANCER STEM CELLS AND ONCOLOGY RESEARCH

June 26-28, 2017 London, UK

Ken H Young

The University of Texas MD Anderson Cancer Center, USA

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

Clinical heterogeneity is a major challenge for the treatment of diffuse large B cell lymphoma (DLBCL). Different cell-of-origin may contribute to the distinct biology of DLBCL as suggested by the germinal center-like and activated B cell (ABC)-like DLBCL classification system. Characterization of biological and genetic parameters underlying the molecular mechanisms help to identify critical targets responsible for drug resistance, treatment failure and recurrence, and it is helpful for better understanding the pathogenesis of DLBCL. In this presentation, the important molecular and biological events are systemically analyzed in a large cohort of de novo DLBCL patients to evaluate for the correlation of biological and genetic parameters with clinical outcome using high-throughput next generation sequencing (NGS). Gene expression and epigenetic miRNA profiling have also been explored for particular signature from each of the patients based on B-cell differentiation. Combined genetic, clinical and pathologic dissections provide insight in better understanding of the cell-of-origin, drug resistance, and recurrence in DLBCL patients.

Biography :

Email: khyoung@mdanderson.org